Equities

DaShenLin Pharmaceutical Group Co Ltd

603233:SHH

DaShenLin Pharmaceutical Group Co Ltd

Actions
Consumer Staples Personal Care, Drug and Grocery Stores
  • Price (CNY)12.16
  • Today's Change-3.92 / -24.38%
  • Shares traded10.32m
  • 1 Year change-52.35%
  • Beta1.0468
Data delayed at least 15 minutes, as of Sep 13 2024 08:00 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Forecasts data is unavailable for this security.

Consensus recommendation

  • 14-Dec-23
  • 19-Sep-24
  • 17-Oct-24
  • 14-Nov-24
Select bar for recommendation details.
Recommendations14-Nov-24
Buy5
Outperform9
Hold0
Sell0
Strong Sell1

Share price forecast in CNY

The 9 analysts offering 12 month price targets for Dashenlin Pharmaceutical Group Co Ltd have a median target of 24.00, with a high estimate of 34.00 and a low estimate of 12.00. The median estimate represents a 49.25% increase from the last price of 16.08.
High111.4%34.00
Med49.3%24.00
Low-25.4%12.00

Dividends in CNY

In 2023, DaShenLin Pharmaceutical Group Co Ltd reported a dividend of 0.31 CNY, which represents a 38.00% decrease from last year. The 8 analysts covering the company expect dividends of 0.37 CNY for the upcoming fiscal year, an increase of 20.00%.
Div growth (TTM)-38.00%
More ▼

Earnings history & estimates in CNY

On Oct 30, 2024, Dashenlin Pharmaceutical Group Co Ltd reported 3rd quarter 2024 earnings of 0.17 per share.
Average growth rate-53.46%
Dashenlin Pharmaceutical Group Co Ltd reported annual 2023 earnings of 1.03 per share on Apr 28, 2024.
Average growth rate+18.10%
More ▼

Revenue history & estimates in CNY

Dashenlin Pharmaceutical Group Co Ltd had 3rd quarter 2024 revenues of 6.39bn. This bettered the 6.36bn consensus of the 2 analysts covering the company. This was 7.38% above the prior year's 3rd quarter results.
Average growth rate+3.12%
Dashenlin Pharmaceutical Group Co Ltd had revenues for the full year 2023 of 24.53bn. This was 18.05% above the prior year's results.
Average growth rate+22.05%
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.